JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB222515

Anti-CDA antibody [EPR20525]

Be the first to review this product! Submit a review

|

(6 Publications)

Rabbit Recombinant Monoclonal CDA antibody. Suitable for WB, Flow Cyt (Intra), IHC-P and reacts with Human samples. Cited in 6 publications.

View Alternative Names

CDD, CDA, Cytidine deaminase, Cytidine aminohydrolase

7 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CDA antibody [EPR20525] (AB222515)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CDA antibody [EPR20525] (AB222515)

Immunohistochemical analysis of paraffin-embedded human normal colon (panel A) and colon cancer (panel B) tissues labeling CDA with ab222515 at 1/2000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use. Cytoplasmic and nuclear staining on sporadic stromal cells of human normal colon tissue, while adjacent cancer cells and some stromal cells show moderate positive staining. The IHC signal on human colon cancer tissue was higher than its corresponding normal tissue (PMID : 9849491). Counter stained with Hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CDA antibody [EPR20525] (AB222515)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CDA antibody [EPR20525] (AB222515)

Immunohistochemical analysis of paraffin-embedded human normal liver (panel A) and liver cancer (panel B) tissues labeling CDA with ab222515 at 1/2000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use. Cytoplasmic and nuclear staining on normal human liver tissues, with only sporadic stromal cells showing positive staining in human liver cancer. The IHC signal on human liver cancer tissue was much lower than its corresponding normal tissue (PMID : 9849491). Counter stained with Hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Flow Cytometry (Intracellular) - Anti-CDA antibody [EPR20525] (AB222515)
  • Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-CDA antibody [EPR20525] (AB222515)

Intracellular flow cytometric analysis of 4% paraformaldehyde-fixed, 90% methanol permeabilized HeLa (humanepithelialcell line from cervix adenocarcinoma) cell line labeling CDA with ab222515 at 1/70 dilution (red) compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CDA antibody [EPR20525] (AB222515)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CDA antibody [EPR20525] (AB222515)

Immunohistochemical analysis of paraffin-embedded human spleen tissue labeling CDA with ab222515 at 1/2000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use. Nuclear and cytoplasmic staining on neutrophils of human spleen (PMID : 11069255). Counter stained with Hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Western blot - Anti-CDA antibody [EPR20525] (AB222515)
  • WB

Lab

Western blot - Anti-CDA antibody [EPR20525] (AB222515)

Western blot : Rabbit Monoclonal [EPR20525] to CDA ab222515 staining at 1/1000 dilution, shown in green; Mouse anti GAPDH (ab8245) loading control staining at 1/20,000 dilution, shown in magenta.

A band was observed at 16 kDa in Wild-type A549 cell lysates with no signal observed at this size in CDA knockout A549 cell line.

To generate this image, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3pc Milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged.

Secondary antibodies used were Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20,000 dilution.

All lanes:

Western blot - Anti-CDA antibody [EPR20525] (ab222515) at 1/1000 dilution

Lane 1:

Wild-type A549 at 20 µg

Lane 2:

CDA knockout A549 at 20 µg

Lane 2:

Western blot - Human CDA knockout A549 cell line (<a href='/en-us/products/cell-lines/human-cda-knockout-a549-cell-line-ab300883'>ab300883</a>) at 20 µg

Lane 3:

Wild-type HCT at 20 µg

Lane 4:

CDA knockout HCT at 20 µg

Secondary

All lanes:

Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20000 dilution

Predicted band size: 16 kDa

Observed band size: 16 kDa

false

Western blot - Anti-CDA antibody [EPR20525] (AB222515)
  • WB

Lab

Western blot - Anti-CDA antibody [EPR20525] (AB222515)

Western blot : Rabbit Monoclonal [EPR20525] to CDA ab222515 staining at 1/1000 dilution, shown in green; Mouse anti GAPDH (ab8245) loading control staining at 1/20,000 dilution, shown in magenta.

A band was observed at 17 kDa in Wild-type HCT 116 cell lysates with no signal observed at this size in cda knockout HCT 116 cell line.

To generate this image, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3pc Milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged.

Secondary antibodies used were Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20,000 dilution.

All lanes:

Western blot - Anti-CDA antibody [EPR20525] (ab222515) at 1/1000 dilution

Lane 1:

Wild-type HCT 116 at 20 µg

Lane 2:

CDA knockout HCT 116 at 20 µg

Lane 2:

Western blot - Human CDA knockout HCT116 cell line (ab300882) at 20 µg

Lane 3:

HepG2 at 20 µg

Lane 4:

MCF7 at 20 µg

Secondary

All lanes:

Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20000 dilution

Predicted band size: 16 kDa

Observed band size: 17 kDa

false

Western blot - Anti-CDA antibody [EPR20525] (AB222515)
  • WB

Supplier Data

Western blot - Anti-CDA antibody [EPR20525] (AB222515)

Exposure times : Lane 1 : 3 minutes; Lane 2 : 8 seconds; Lanes 3/5 : 5 seconds; Lane 4 : 30 seconds.

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-CDA antibody [EPR20525] (ab222515) at 1/1000 dilution

Lane 1:

HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 10 µg

Lane 2:

Human fetal spleen lysate at 10 µg

Lane 3:

HepG2 (human liver hepatocellular carcinoma cell line) whole cell lysate at 10 µg

Lane 4:

TF-1 (human bone marrow erythroleukemia cell line) whole cell lysate at 10 µg

Lane 5:

Human fetal kidney lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 16 kDa

Observed band size: 16 kDa

true

  • Carrier free

    Anti-CDA antibody [EPR20525] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR20525

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB, Flow Cyt (Intra), IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/70", "FlowCytIntra-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/2000", "IHCP-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Conditional Ambient
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cytidine deaminase (CDA) also known as CDD is a zinc-dependent enzyme responsible for deaminating cytidine. The full form of CDA has a molecular mass of approximately 41 kDa. CDA is widely expressed in various tissues including liver kidney and leukocytes. It plays an important role in nucleotide metabolism by converting cytidine to uridine and 2'-deoxycytidine to 2'-deoxyuridine which impacts nucleic acid stability and synthesis. Researchers frequently use techniques such as ELISA and Western blotting to study CDA expression and activity often referencing it in contexts like "CDA Western" or "57 seconds CDA."
Biological function summary

CDA enzyme influences the pyrimidine salvage pathway by facilitating nucleotide degradation and recycling. It operates independently rather than as part of a protein complex. The activity of this enzyme ensures a balanced nucleotide pool essential for DNA replication and repair processes. This balance affects cellular proliferation and survival highlighting the importance of studying CDA protein in normal physiology and various pathological conditions.

Pathways

CDA contributes significantly to pyrimidine metabolism and its recycling pathway. It maintains a connection with ribonucleotide reductase which plays a role in the regulation of deoxyribonucleotide pools during DNA synthesis. This interplay highlights the enzyme’s involvement in DNA repair pathways ensuring proper cell division and genomic integrity. Within these pathways enzymes like cytidine triphosphate synthetase also relate to CDA by participating in nucleotide homeostasis.

Improper CDA function is linked to specific cancers including acute myeloid leukemia due to altered nucleotide metabolism leading to genomic instability. The enzyme's activity also affects the pharmacokinetics of cytidine analogues like gemcitabine used in cancer treatment. CDA overexpression might result in reduced drug efficacy thereby hindering therapy in affected patients. Connections exist between CDA and proteins involved in chemoresistance such as ribonucleotide reductase showing its significance in treatment outcomes.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.
See full target information CDA

Publications (6)

Recent publications for all applications. Explore the full list and refine your search

PloS one 20:e0331289 PubMed40892739

2025

CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells.

Applications

Unspecified application

Species

Unspecified reactive species

Kun-Lin Hsieh,Kuan-Hua Huang,Ching-Ping Chang,Hung-Wen Tsai,Yu-Hao Chang,Yi-Ru Zheng,Huei-Sheng Huang

Discover oncology 16:1066 PubMed40504344

2025

Differential expression of capecitabine-related metabolic enzymes in hepatocellular carcinoma and its clinical value: a retrospective cohort study.

Applications

Unspecified application

Species

Unspecified reactive species

Jianing Lu,Zhiqi Yin,Yan Zhuang,Zhenglu Wang,Hong Zheng,Lei Cao,Dejun Kong,Jinliang Duan,Shaofeng Chen,Tao Chen

International journal of molecular sciences 24: PubMed37108401

2023

A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance.

Applications

Unspecified application

Species

Unspecified reactive species

Luis Vergara-Gómez,Carolina Bizama,Jun Zhong,Kurt Buchegger,Felipe Suárez,Lorena Rosa,Carmen Ili,Helga Weber,Javiera Obreque,Karena Espinoza,Gabriela Repetto,Juan C Roa,Pamela Leal,Patricia García

Experimental & molecular medicine 54:1236-1249 PubMed35999456

2022

DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy.

Applications

Unspecified application

Species

Unspecified reactive species

Haejeong Heo,Jong-Hwan Kim,Hyun Jung Lim,Jeong-Hwan Kim,Miso Kim,Jaemoon Koh,Joo-Young Im,Bo-Kyung Kim,Misun Won,Ji-Hwan Park,Yang-Ji Shin,Mi Ran Yun,Byoung Chul Cho,Yong Sung Kim,Seon-Young Kim,Mirang Kim

Molecular cancer 21:24 PubMed35045883

2022

circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis.

Applications

Unspecified application

Species

Unspecified reactive species

Chonghui Hu,Renpeng Xia,Xiang Zhang,Tingting Li,Yuancheng Ye,Guolin Li,Rihua He,Zhihua Li,Qing Lin,Shangyou Zheng,Rufu Chen

Journal of cellular and molecular medicine 25:8127-8139 PubMed34350711

2021

Overexpression of let-7d explains down-regulated KDM3A and ENO2 in the pathogenesis of preeclampsia.

Applications

Unspecified application

Species

Unspecified reactive species

Qian Xu,Yonghui Song,Lili Lu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com